MedPath

Memphasys Nears Completion of Key Trial for Felix™ System

• Memphasys is nearing completion of a key trial for its Felix™ System, designed to improve IVF outcomes by separating high-quality sperm. • The Felix™ System aims to address the challenges of sperm selection in assisted reproductive technologies, potentially increasing fertilization rates. • Final data analysis and reporting are underway, with results expected to inform future commercialization and clinical applications of the system.

Memphasys is in the final stages of a crucial trial for its Felix™ System, a device engineered to enhance sperm selection for assisted reproductive technologies. The trial's completion marks a significant step toward potentially improving in vitro fertilization (IVF) outcomes.
The Felix™ System is designed to address a critical need in reproductive medicine: the efficient separation of high-quality sperm from a semen sample. This selection process is vital for successful fertilization and subsequent embryo development. By isolating sperm with superior motility and morphology, the Felix™ System aims to increase the likelihood of successful IVF cycles.
Currently, the company is focused on the final data analysis and report generation. The results from this trial are expected to provide valuable insights into the system's efficacy and inform future commercialization strategies. The data will also be crucial for guiding clinical applications and further development of the Felix™ System.
The successful completion of this trial represents a key milestone for Memphasys, potentially paving the way for a new approach to sperm selection in assisted reproduction.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Xeltis Completes Enrollment in EU Pivotal Trial for aXess Vascular Access Conduit

Xeltis has completed enrollment in its EU pivotal trial for aXess, a restorative vascular access conduit, for adults with end-stage renal disease.
The trial, conducted across 22 centers in Europe, enrolled 120 patients to assess aXess's patency, safety, and performance for hemodialysis.

Mirum Pharmaceuticals to Launch Phase 2 Trial of MRM-3379 for Fragile X Syndrome

Mirum Pharmaceuticals plans to initiate a Phase 2 clinical trial of MRM-3379, an oral treatment for fragile X syndrome, in 2025.
MRM-3379 selectively blocks phosphodiesterase 4D (PDE4D), an enzyme involved in nerve cell communication, aiming to increase cAMP levels in the brain.

Xeltis' aXess Receives FDA Breakthrough Device Designation and Enrolls First Patient in Pivotal Trial

Xeltis' aXess, a synthetic vascular access device, has been granted Breakthrough Device designation by the FDA, expediting its path to market.
The pivotal trial, a prospective, single-arm, multi-center study, is evaluating the safety and performance of aXess in adults with end-stage renal disease needing dialysis.

Xeltis' aXess Receives FDA Breakthrough Device Designation and Enrolls First Patient in Pivotal Trial

Xeltis' aXess, a synthetic vascular access device, has been granted Breakthrough Device designation by the FDA, expediting its path to market through prioritized review and enhanced interaction with FDA experts.
The company has enrolled and treated the first patient in its US pivotal trial, a prospective, single-arm, multi-center study evaluating the safety and performance of aXess in adults with end-stage renal disease needing dialysis.

Spectral Medical's Tigris Trial Nears Completion as Revenue Rises

Spectral Medical reported a 54% revenue increase in Q2, driven by progress in its Tigris trial for Toraymyxin, a septic shock treatment.
The Tigris trial, evaluating Toraymyxin in endotoxemia and septic shock patients, has randomized 126 of the targeted 150 patients across 23 sites.

Xeltis' aXess Receives FDA IDE Approval for US Pivotal Trial in Hemodialysis Vascular Access

Xeltis has received FDA approval for an Investigational Device Exemption (IDE) to initiate a US pivotal trial for its aXess vascular access conduit.
aXess is designed to create a new, living vessel for hemodialysis, combining the benefits of arteriovenous fistulas and grafts, potentially reducing complications.

Dimerix's DMX-200 Shows Promise in Phase 3 Trial for Rare Kidney Disease FSGS

Dimerix Limited's DMX-200 demonstrates successful interim results in a Phase 3 trial for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease.
The trial included 72 patients and showed potential in treating FSGS, which currently has no approved drugs globally, marking a significant advancement.

Xeltis Initiates Pivotal Trial for aXess Graft in Hemodialysis Patients

Xeltis has commenced a pivotal European clinical trial to assess the safety and efficacy of its aXess graft in patients with end-stage renal disease requiring hemodialysis.
The prospective, single-arm study aims to enroll 110 patients across up to 25 European centers, monitoring them over five years post-implantation.

Xeltis Initiates Pivotal Trial for aXess Hemodialysis Access Graft

Xeltis has begun a pivotal clinical trial for aXess, a novel restorative synthetic graft for hemodialysis access, with successful implantation in the first two patients.
The AXESS European pivotal trial will enroll 110 patients across up to 25 centers in Europe to assess the safety and performance of aXess over five years.

Reference News

[1]
Memphasys Nears Completion of Key Trial for Felix™ System - TipRanks.com
tipranks.com · Nov 17, 2024

Memphasys Ltd (AU:MEM) is close to completing its Felix™ System clinical trial, with 95% patient recruitment achieved. T...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy